\
&
Contact us
\
&
Contact us
Published on | 5 months ago
ProgrammesThe Joint Research Centre (JRC) of the Commission invites applications for hands-on training at its state-of-the-art Nanobiotechnology Laboratory. This call offers researchers the opportunity to strengthen expertise in nanomaterials, nanomedicines, advanced materials, and micro(nano)plastics, with a focus on their detection, characterisation, and interactions with biological systems. This is a unique opportunity to access cutting-edge facilities and multidisciplinary expertise at the JRC.
Training and capacity building priorities:
Early-career scientists are strongly encouraged to apply. Provisional dates of the training: 23-27 March 2026, Ispra, Italy.
More information and application: 2025-1-TCB-NanoBiotech - Nanobiotechnology laboratory - The Joint Research Centre: EU Science Hub. Deadline to apply: 28 November 2025, 23:45 (CET)
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital Europe AI Continent Advanced Digital Skills Deployment: Best use of technologies
The following call topics under the Digital Europe programme are now open for submission: Apply AI: Piloting AI-based image screening in medical centres Digital solutions for regulatory compliance through data Advanced Digital Skills for AI Uptake in Health EdTech Accelerator Digital Skills and Jobs Platform: The National Coalitions for Digi... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
